Immune Checkpoints on Gamma Delta T Cells Follow Their Own Rules, Study Finds

Immune checkpoint receptors have become some of the most closely watched molecules in modern medicine, the molecular brakes that tumors exploit to quiet the T cells hunting them. Drugs that release these brakes, known as immune checkpoint blockade, have transformed the treatment of melanoma, lung cancer, and many other malignancies. Yet the interpretation of checkpoint expression has long rested on studies of conventional alpha-beta T cells, leaving a major branch of the immune system largely uncharted. A new study published in the Journal of Translational Medicine by Anna Maria Corsale, Marta Di Simone, Juan Pablo Cerapio, Serena Meraviglia, and colleagues at the University of Palermo and partner institutions now maps how these regulatory receptors behave on human gamma delta T cells, and the picture that emerges is strikingly different from the textbook alpha-beta narrative.

Gamma delta T cells occupy a curious middle ground in immunology. Unlike their alpha-beta cousins, which recognize peptide fragments presented by major histocompatibility molecules, gamma delta T cells can respond to phosphoantigens, small metabolite-like molecules that accumulate in stressed and transformed cells. This unconventional recognition has made them attractive targets for cancer immunotherapy, and clinical efforts to expand and harness them are underway worldwide. But if gamma delta T cells are to be deployed rationally in the clinic, researchers need to know which checkpoint receptors they carry, when those receptors appear, and what they actually mean for cell function. The new work addresses precisely this gap, and its central message is that checkpoint expression on gamma delta T cells is governed by receptor identity, T-cell lineage, and environmental context all at once.

The experimental design combined laboratory manipulation of living cells with computational mining of published single-cell datasets. The team isolated peripheral blood mononuclear cells from healthy donors and stimulated them in vitro under different conditions, then used flow cytometry to track how checkpoint receptor expression changed over time on both gamma delta and alpha-beta T-cell subsets. In parallel, they reanalyzed previously published single-cell RNA-sequencing data from tumor-infiltrating gamma delta and CD8 T cells, looking for how checkpoint expression was distributed across differentiation states and how it shifted in patients who had received immune checkpoint blockade therapy. This dual approach allowed the researchers to connect what happens in a culture dish with what happens inside human tumors.

The first major finding concerned how different modes of stimulation produce different checkpoint profiles. When the researchers applied polyclonal stimulation, a blunt activation signal that drives many T cells at once, they observed a broad upregulation of checkpoint receptors across the board. But when they expanded V delta 2 T cells, the dominant gamma delta subset in human blood, using phosphoantigen-driven activation, the resulting profile was far more selective. TIM-3 expression rose and remained sustained, while PD-1 and TIGIT showed only transient modulation. In other words, the way a gamma delta T cell is activated leaves a lasting imprint on which brakes it carries, a detail that could matter enormously for clinical protocols that expand these cells ex vivo before infusion into patients.

The second key insight came from mapping checkpoint receptors onto the differentiation journey of T cells. T cells progress through recognizable stages, from naive cells that have never met their antigen, through central memory and effector memory populations, to terminally differentiated effector memory cells. The researchers found that checkpoint distribution was structured along this trajectory, but not in a uniform way. TIGIT was enriched in antigen-experienced subsets, consistent with its association with repeated antigen encounter. LAG-3 and TIM-3, by contrast, were concentrated in naive compartments, an unexpected pattern that challenges the assumption that these receptors simply mark worn-out cells. PD-1 was expressed broadly, appearing across multiple differentiation states rather than clustering at any single stage.

These distribution patterns carry a pointed implication: checkpoint receptor expression alone cannot be used as a proxy for T-cell exhaustion. In alpha-beta T-cell biology, high PD-1 expression is often read as a sign of a dysfunctional, exhausted state that checkpoint blockade can rescue. But the Palermo team’s data show that gamma delta T cells can display checkpoint receptors as a normal feature of activation and differentiation, without any evidence of functional collapse. The authors are careful on this point, noting that because classical exhaustion-associated transcriptional and epigenetic programs were not evaluated in their study, the observed patterns neither establish nor exclude the presence of exhausted gamma delta T-cell subsets. What the data do establish is that checkpoint expression is dynamically shaped by activation history, differentiation state, and environmental context, making single-marker interpretations unreliable.

Functionally, the team tested what happens when the brakes are released. Blocking PD-1 produced donor-dependent trends toward increased proliferation and cytokine production, an effect that was particularly noticeable when the cells were cultured with interleukin-15, a cytokine known to support gamma delta T-cell survival and cytotoxicity. The donor-to-donor variability is itself informative, suggesting that the responsiveness of a patient’s gamma delta T cells to checkpoint blockade may depend on their individual immune baseline. TIM-3 inhibition, meanwhile, showed variable effects across experiments, and combining PD-1 and TIM-3 blockade did not produce a consistent additive response. For a field increasingly interested in combination checkpoint therapies, this absence of synergy in gamma delta T cells is a caution against assuming that strategies validated in alpha-beta biology will transfer cleanly.

The single-cell transcriptomic analysis added a tumor-side perspective. When the researchers examined tumor-infiltrating gamma delta T cells from published datasets, they found heterogeneous checkpoint expression scattered across differentiation states, with no single coherent pattern. CD8 alpha-beta T cells from the same tumors, in comparison, showed a more progressive, stepwise accumulation of checkpoint expression as they differentiated. This lineage-specific architecture suggests that gamma delta T cells inside tumors do not follow the same trajectory of escalating checkpoint burden that characterizes conventional cytotoxic T cells. Intriguingly, the analysis of samples from patients who had undergone immune checkpoint blockade therapy revealed that alternative checkpoint receptors tended to persist or even increase after treatment, hinting at compensatory mechanisms that could blunt therapeutic responses.

The translational stakes of this work are considerable. Gamma delta T cells are being pursued as cellular therapies for cancer, and several approaches involve expanding V delta 2 T cells with aminobisphosphonates such as zoledronic acid, which causes phosphoantigen accumulation in target cells. The finding that phosphoantigen-driven expansion produces a distinctive checkpoint signature, with sustained TIM-3 and only transient PD-1 modulation, gives therapy developers a molecular fingerprint to monitor and potentially manipulate. If the checkpoint profile of an infused gamma delta product determines how long it survives and functions in a patient, then tuning the expansion conditions becomes a rational design parameter rather than an afterthought. Similarly, the donor-dependent response to PD-1 blockade under interleukin-15 stimulation suggests that biomarker-guided patient selection could improve the odds of combination regimens involving gamma delta cells.

Beyond the immediate clinical implications, the study is a reminder that immunology’s most influential paradigms are built on a fraction of the immune system’s diversity. Checkpoint receptors are not a single switch with a single meaning; they are a family of regulatory molecules whose expression and function depend on which T-cell lineage carries them, how that cell was activated, and where it finds itself. For gamma delta T cells, the brakes may be part of the normal operating machinery rather than a sign of breakdown. Disentangling genuine exhaustion from routine checkpoint expression will require integrating receptor measurements with transcriptional and epigenetic profiling, work that the authors flag as the necessary next step. As gamma delta T-cell therapies move closer to the clinic, studies like this one provide the context-dependent framework that careful translation demands, ensuring that the next generation of immunotherapies is designed around how these unconventional cells actually behave.

Subject of Research: Immune checkpoint receptor dynamics in human gamma delta T cells

Article Title: Lineage-specific immune checkpoint dynamics define a context-dependent regulatory framework with translational relevance in human γδ T cells

Article References: Corsale, A. M., Di Simone, M., Cerapio, J. P., Lo Presti, E., Pizzolato, G., Avellone, C., Dieli, C., Marchiafava, S., Di Paola, L., Dieli, F., & Meraviglia, S. (2026). Lineage-specific immune checkpoint dynamics define a context-dependent regulatory framework with translational relevance in human γδ T cells. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09004-1

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09004-1

Keywords: gamma delta T cells, immune checkpoint receptors, immune checkpoint blockade, T-cell exhaustion, PD-1, TIM-3, TIGIT, LAG-3, single-cell RNA sequencing, cancer immunotherapy, Vdelta2 T cells, flow cytometry